Your session is about to expire
← Back to Search
Bioavailability Study of Psilocybin in Normal Adults
Phase 1
Waitlist Available
Led By Christopher Nicholas, PhD
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 8, day 22
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing psilocybin, taken as a pill or through an IV, in healthy adults. The study aims to see how the body absorbs it and its effects. Psilocybin turns into psilocin in the body, which causes the psychedelic experience. Psilocybin is a naturally occurring tryptamine known for its psychedelic properties and has been studied for its potential to treat depression and anxiety.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 8, day 22
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 8, day 22
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Determine the concentration of psilocin following oral and IV administrations of psilocybin
Determine the maximum concentration of psilocin following oral and IV administrations of psilocybin
Difference in the area under plasma concentration-time curve (AUC) between psilocybin administration methods.
+2 moreSecondary study objectives
Characterize the incidence and severity of adverse events associated with doses of psilocybin in healthy adults
Suicidal ideation
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Oral and IV psilocybinExperimental Treatment2 Interventions
Psilocybin with psychological support: Psilocybin will be administered in the form of capsules, taken orally with water, at one visit. Psilocybin will be administered through IV at the other visit.
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
TRYP TherapeuticsIndustry Sponsor
3 Previous Clinical Trials
34 Total Patients Enrolled
University of Wisconsin, MadisonLead Sponsor
1,234 Previous Clinical Trials
3,200,291 Total Patients Enrolled
Christopher Nicholas, PhDPrincipal InvestigatorUniversity of Wisconsin, Madison
2 Previous Clinical Trials
17 Total Patients Enrolled
Paul Hutson, PharmDPrincipal InvestigatorUniversity of Wisconsin, Madison
1 Previous Clinical Trials
12 Total Patients Enrolled